HSP90-IN-31

HSP90-IN-31 (compound Be01) causes reduction of CD80 and CD86 expression on dendritic cells (DCs) . HSP90-IN-31 decreases the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in BMDC and peritoneal macrophages stimulated by LPS (HY-D1056) . Under the delayed-type hypersensitivity (DTH) mice model, HSP90-IN-31 reduces ear swelling and pro-inflammatory cytokines in the spleen[1].

Product Specifications

CAS Number

[2117645-10-8]

UNSPSC

12352005

Target

Interleukin Related; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/hsp90-in-31.html

Smiles

CC(C)C1=C(O)C=C(O)C(C(N(C)CC2=CC=C(C(NCCC)=O)C=C2)=O)=C1

Molecular Formula

C22H28N2O4

Molecular Weight

384.47

References & Citations

[1]Hyun Bo Sim, et al. Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation. Int Immunopharmacol. 2024 Aug 20:137:112470.